CENTOGENE today announced the initiation of \u2018PICOPglobal\u2019\u00a0 \u0336 \u00a0a 24-month global proof-of concept study focusing on the identification of tumor-specific neoantigens as the basis for developing a personalized, immune-based therapy to trigger patients\u2019 own immune responses against tumors. The PICOPglobal study is being conducted without a treatment arm and in collaboration with the Surgical Oncology Society Pakistan. Local partners or the University of Rostock and University of Greifswald in Germany.<\/p>\n
The study aims to enroll 100 participants with pancreas or colorectal carcinoma in order to analyze the molecular characteristics of tumors and to subsequently identify tumor-specific antigens (neoepitopes). These neoepitopes are powerful targets for future patient-individualized vaccination since enhancement of the immune response via vaccination is among new therapeutic options by using either cell-specific antigens, over-expressed tumor-specific antigens, or mutated neoepitopes.<\/p>\n
Tumor and control samples will be tested genetically to identify tumor associated mutations and MS\/MS-based mutations to identify neoepitopes and biomarkers. The collected data will be used in a multi-omics approach to possibly predict neoepitopes suitable for use in vaccines.<\/p>\n
\u201cWith the high incidences and poor prognosis of Colon- and Pancreas-Carcinoma especially in developing countries, there is an urgent need to improve treatment for patients.\u201d said Dr. Peter Bauer, MD, Chief Scientific Officer, CENTOGENE. \u201cWe are proud to be working on this important study that may have a considerable impact on cancer immunotherapy and individualized treatment for patients via peptide-based immunization for Colon- and Pancreas-Carcinoma. We are excited about the contribution that CENTOGENE and our international partners will be making ultimately for the benefit of cancer patients worldwide.\u201d<\/p>\n
\u201cWe are excited to be partners in this global collaboration which has the potential of advancing our understanding of cancer biology and immunology,\u201d added Prof. Muhammad Arshad Cheema, University of Lahore, during a recent visit to CENTOGENE in Rostock. \u201cThe members of Surgical Oncology Society Pakistan look forward to the day when we can hopefully translate the knowledge gained from this study to an effective vaccine for our cancer patients.\u201d<\/p>\n